China to release blacklist for corporate bribery

|By:, SA News Editor

China is developing a blacklist on which it will place manufacturers of medical products that have been charged with, sued for, or investigated in connection with bribery.

Companies that land on the list will reportedly be banned from operating in the province where they were accused, while those firms that make the list twice in any five-year period could get a two-year national ban.

Both GlaxoSmithKline (GSK +0.9%) and Danone SA (DANOY +1.5%) have been variously accused in China.